DE69508875T2 - Amidinophenol-Derivate als Protease-hemmende Verbindungen - Google Patents
Amidinophenol-Derivate als Protease-hemmende VerbindungenInfo
- Publication number
- DE69508875T2 DE69508875T2 DE69508875T DE69508875T DE69508875T2 DE 69508875 T2 DE69508875 T2 DE 69508875T2 DE 69508875 T DE69508875 T DE 69508875T DE 69508875 T DE69508875 T DE 69508875T DE 69508875 T2 DE69508875 T2 DE 69508875T2
- Authority
- DE
- Germany
- Prior art keywords
- formula
- compounds
- diseases
- pancreatitis
- con
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- IYELGEUXPAPULN-UHFFFAOYSA-N 2-hydroxybenzenecarboximidamide Chemical class NC(=N)C1=CC=CC=C1O IYELGEUXPAPULN-UHFFFAOYSA-N 0.000 title 1
- 108091005804 Peptidases Proteins 0.000 title 1
- 239000004365 Protease Substances 0.000 title 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 206010033645 Pancreatitis Diseases 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 208000026935 allergic disease Diseases 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- RXGNLDFDLLMAJZ-UHFFFAOYSA-N 3-bromo-1,2-oxazole-5-carbaldehyde Chemical compound BrC=1C=C(C=O)ON=1 RXGNLDFDLLMAJZ-UHFFFAOYSA-N 0.000 abstract 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010061216 Infarction Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000034486 Multi-organ failure Diseases 0.000 abstract 1
- 208000010718 Multiple Organ Failure Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 abstract 1
- 102000004142 Trypsin Human genes 0.000 abstract 1
- 108090000631 Trypsin Proteins 0.000 abstract 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 abstract 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 abstract 1
- 238000001631 haemodialysis Methods 0.000 abstract 1
- 230000000322 hemodialysis Effects 0.000 abstract 1
- 230000007574 infarction Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 abstract 1
- 208000004235 neutropenia Diseases 0.000 abstract 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 1
- 125000005702 oxyalkylene group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 208000018556 stomach disease Diseases 0.000 abstract 1
- 239000012588 trypsin Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/14—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/16—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/32—Esters thereof
- C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/3241—Esters of arylalkanephosphinic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4015—Esters of acyclic unsaturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25015894 | 1994-09-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69508875D1 DE69508875D1 (de) | 1999-05-12 |
| DE69508875T2 true DE69508875T2 (de) | 1999-09-16 |
Family
ID=17203690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69508875T Expired - Fee Related DE69508875T2 (de) | 1994-09-20 | 1995-09-19 | Amidinophenol-Derivate als Protease-hemmende Verbindungen |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US6262114B1 (de) |
| EP (1) | EP0703216B1 (de) |
| KR (1) | KR100226619B1 (de) |
| AT (1) | ATE178589T1 (de) |
| CA (1) | CA2158676A1 (de) |
| DE (1) | DE69508875T2 (de) |
| DK (1) | DK0703216T3 (de) |
| ES (1) | ES2132535T3 (de) |
| GR (1) | GR3030433T3 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0893437A4 (de) | 1996-04-10 | 2000-12-27 | Ono Pharmaceutical Co | Tryptase-Inhibitor und Guanidino-Derivate |
| EP0942903A1 (de) | 1996-09-26 | 1999-09-22 | Novartis AG | Arylsubstituierte acrylamine mit leukotriene b4-(ltb-4)-rezeptor antagonistischer aktivität |
| CA2394639A1 (en) * | 1999-12-15 | 2001-06-21 | Danny Peter Claude Mcgee | Salicylamides as serine protease and factor xa inhibitors |
| DE10110749A1 (de) * | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| US7507531B2 (en) | 2002-10-17 | 2009-03-24 | Decode Genetics Chf. | Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction |
| US7851486B2 (en) | 2002-10-17 | 2010-12-14 | Decode Genetics Ehf. | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment |
| US20050272051A1 (en) * | 2003-09-17 | 2005-12-08 | Decode Genetics Ehf. | Methods of preventing or treating recurrence of myocardial infarction |
| US8158362B2 (en) | 2005-03-30 | 2012-04-17 | Decode Genetics Ehf. | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype |
| US7723396B2 (en) * | 2006-12-22 | 2010-05-25 | Rohm And Haas Company | Foam composites with emulsion polymer films |
| EP2147935B1 (de) * | 2008-07-02 | 2011-12-28 | Rohm and Haas Company | Emulsionspolymerhaftmittel |
| US8445008B2 (en) * | 2008-10-17 | 2013-05-21 | Medtronic, Inc. | Reduction of infection associated with medical device |
| WO2011071048A1 (ja) * | 2009-12-07 | 2011-06-16 | 味の素株式会社 | ヘテロアリールカルボン酸エステル誘導体 |
| CN102225903B (zh) * | 2011-04-21 | 2014-11-26 | 任建东 | 脒基胍基取代芳杂环类化合物的合成方法及其用途 |
| US9024044B2 (en) | 2012-06-14 | 2015-05-05 | Ajinomoto Co., Inc. | Heteroarylcarboxylic acid ester derivative |
| RU2619860C1 (ru) * | 2016-04-15 | 2017-05-18 | Федеральное государственное бюджетное учреждение науки Иркутский институт химии им. А.Е. Фаворского Сибирского отделения Российской академии наук | Применение протатран 4-хлор-2-метилфеноксиацетата для угнетения суммарной активности основной (щелочной) фосфолипазы а2 мононуклеаров |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE555319A (de) | 1956-03-21 | 1900-01-01 | ||
| CH520657A (de) * | 1961-09-11 | 1972-03-31 | Wander Ag Dr A | Verfahren zur Herstellung mehrbasischer Verbindungen |
| US3095355A (en) | 1961-10-12 | 1963-06-25 | Revlon | Aerosol composition |
| AU527371B2 (en) * | 1980-09-16 | 1983-03-03 | Torii & Co., Ltd. | Amidine |
| JPS60130561A (ja) * | 1983-12-16 | 1985-07-12 | Torii Yakuhin Kk | アミジン誘導体およびそれを含む強心剤 |
| US5418002A (en) | 1990-12-24 | 1995-05-23 | Harris Corporation | Direct bonding of copper to aluminum nitride substrates |
| EP0518818A3 (en) | 1991-06-11 | 1993-04-28 | Ciba-Geigy Ag | Arylethers, their manufacture and use as medicament |
| US5246965A (en) | 1991-06-11 | 1993-09-21 | Ciba-Geigy | Arylethers, their manufacture and methods of treatment |
| US5451700A (en) | 1991-06-11 | 1995-09-19 | Ciba-Geigy Corporation | Amidino compounds, their manufacture and methods of treatment |
| ES2075672T3 (es) | 1991-06-11 | 1995-10-01 | Ciba Geigy Ag | Amidinocompuestos, su fabricacion y uso como medicamento. |
| US5432178A (en) | 1992-09-18 | 1995-07-11 | Ono Pharmaceutical Co., Ltd. | Amidinophenol derivatives |
| ATE164834T1 (de) * | 1993-12-03 | 1998-04-15 | Ono Pharmaceutical Co | Amidinophenolderivate mit phospholipase a2 inhibitorischer wirkung |
-
1995
- 1995-09-19 DE DE69508875T patent/DE69508875T2/de not_active Expired - Fee Related
- 1995-09-19 AT AT95306596T patent/ATE178589T1/de not_active IP Right Cessation
- 1995-09-19 EP EP95306596A patent/EP0703216B1/de not_active Expired - Lifetime
- 1995-09-19 DK DK95306596T patent/DK0703216T3/da active
- 1995-09-19 ES ES95306596T patent/ES2132535T3/es not_active Expired - Lifetime
- 1995-09-19 KR KR1019950030706A patent/KR100226619B1/ko not_active IP Right Cessation
- 1995-09-20 CA CA002158676A patent/CA2158676A1/en not_active Abandoned
-
1997
- 1997-11-21 US US08/975,246 patent/US6262114B1/en not_active Expired - Fee Related
-
1999
- 1999-06-09 GR GR990401519T patent/GR3030433T3/el unknown
-
2001
- 2001-07-03 US US09/897,451 patent/US6583177B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0703216A1 (de) | 1996-03-27 |
| KR960010614A (ko) | 1996-04-20 |
| ATE178589T1 (de) | 1999-04-15 |
| US6583177B2 (en) | 2003-06-24 |
| DK0703216T3 (da) | 1999-10-18 |
| US6262114B1 (en) | 2001-07-17 |
| CA2158676A1 (en) | 1996-03-21 |
| KR100226619B1 (ko) | 1999-10-15 |
| DE69508875D1 (de) | 1999-05-12 |
| US20020128315A1 (en) | 2002-09-12 |
| GR3030433T3 (en) | 1999-09-30 |
| ES2132535T3 (es) | 1999-08-16 |
| EP0703216B1 (de) | 1999-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69508875D1 (de) | Amidinophenol-Derivate als Protease-hemmende Verbindungen | |
| NL300060I1 (nl) | Retrovirale protease remmende verbindingen. | |
| ES2099186T3 (es) | Nuevos inhibidores de elastasa activos por via oral. | |
| HK1055941A1 (en) | Factor viia inhibitory (thio) urea derivatives, their preparation and their use. | |
| EA199900542A1 (ru) | Соединения сульфоновой кислоты или сульфониламино-n-(гетероаралкил)-азагетероциклиламида | |
| ATE214368T1 (de) | Aromatische keto-säure und ihre derivate als inhibitoren der matrix metalloproteinase | |
| DE60214569D1 (de) | Harnstoffverbindungen mit antiproteolytischer wirkung | |
| KR950017929A (ko) | 아미디노페놀 유도체 | |
| HUP0100085A2 (hu) | Bifenilamidinszármazékok és ilyen vegyületeket tartalmazó gyógyászati készítmények | |
| ATE101138T1 (de) | Parabansaeure-derivate und pharmazeutische zusammensetzungen damit. | |
| DE50011645D1 (de) | Sphingomyelinase inhibitoren als wirkstoffe mit antiapoptotischer und antiseptischer wirkung | |
| RU93052161A (ru) | Лекарственные средства, содержащие производные имидазол-1-ила | |
| ATE235900T1 (de) | Hemmer der subepithelialen turbidität | |
| TH18604A (th) | แอริลออกซิแอลคิล ไดแอมีนที่ได้รับการแทนที่วึ่งทำให้หลอมโลหิตบีบตัว | |
| ATE95697T1 (de) | Uricosuretische zusammensetzung. | |
| TH18604EX (th) | แอริลออกซิแอลคิล ไดแอมีนที่ได้รับการแทนที่วึ่งทำให้หลอมโลหิตบีบตัว | |
| ATE71091T1 (de) | Tetrahydro-1,2,4-oxadiazin-5-thion-derivate. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |